🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Lineage Cell Therapeutics, Inc. LCTX PHARMA

Healthcare · Biotechnology · United States
https://www.lineagecell.com
Company Profile ↓
$1.09
+5.83% 1Y
Mkt Cap$275.67M
P/E-5.74
P/B4.27
52W High$1.96
52W Low$1.02
Book Value$0.24
EPS (TTM)$-0.19

Company Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 13.5% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $14.56M (+53.2% YoY); net profit $-63.53M.
  • Trailing 12 Months Year-on-year growth — revenue -61.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.48%
1 Year:-61.30%

Stock Price Performance

1 Year:+5.83%
6 Months:-38.42%
3 Months:-9.92%
1 Month:-0.91%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 7% of range
$1.02 $1.96
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)46.65 · Neutral
Price Performance
1M-0.91%
3M-9.92%
6M-38.42%
1Y+5.83%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 13.5% over 5 years.

CONS

  • Trading 44.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-5.74
Industry PE
24.83
Forward P/E
-10.69
PEG Ratio
10.64
Book Value
$0.24
Price to Book
4.27
P/S
19.91
EV/EBITDA
-8.07
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
13.48%
Profit 5Y
-
Revenue (YoY)
-61.30%
Earnings (YoY)
-

Profitability & Returns

ROCE
-36.18%
ROE
-60.06%
ROA
-17.04%
Profit Margin
-
Op Margin
-
Gross Margin
-57.37%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$-0.19

Balance Sheet & Liquidity

Debt/Equity
3.85
Quick Ratio
6.46
Current Ratio
6.61
Debt
$2.30M
Total Assets
$109.53M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
4.86%
Chg in Prom Hold
-0.07%
FII / Inst Holding
48.20%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$275.67M
Total Revenue (TTM)
$13.08M
EBITDA
$-26.11M
Free Cash Flow
$-14.77M
Operating Cash Flow
$-23.82M
Shares Outstanding
252.91M
Gross Margin
-57.37%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LCTX Lineage Cell Therapeutics, Inc. PHARMA 1.09 -5.74 $275.67M 0.00% -36.18% -60.06% 13.48% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------------------------3.00M-2.39M3.23M1.25M-1.44M1.41M3.78M1.50M2.77M3.68M1.73M
Gross Profit -1.85M1.17M1.44M-333.00K376.00K1.64M-592.00K2.44M947.00K-860.00K672.00K453.00K-420.00K311.00K469.00K-279.00K387.00K1.28M-5.06M4.34M2.76M-2.27M3.10M1.08M--------
Operating Income -21.71M-23.76M-14.40M-9.55M-11.25M-11.26M-8.56M-9.51M-9.56M-12.19M-9.14M-10.36M-10.11M-12.76M-10.82M-8.42M-6.87M-7.44M-6.40M-6.72M-5.88M-7.05M-7.08M-6.84M-28.24M-6.40M-4.23M-5.25M-6.64M-6.64M-5.02M-6.71M-6.36M-6.66M-5.87M-3.84M-6.50M-19.78M-3.79M-7.59M
Net Income -13.51M-17.11M24.55M31.20M-4.95M49.29M-11.65M14.32M-71.93M-63.55M-4.21M66.72M-44.95M39.31M-30.03M-16.50M-4.48M-8.40M-6.52M-7.76M2.03M-1.42M-4.79M-7.82M-28.99M-7.09M-6.76M-6.07M-6.35M-4.37M-5.23M-7.11M-4.78M-6.54M-5.76M-3.03M-4.14M-30.46M-29.78M-4.81M
Diluted EPS --0.190.260.30-0.46-0.110.12--0.50-0.030.53-0.30-0.20-0.11--0.06-0.04-0.05--0.01-0.03-0.05--0.04-0.04-0.04-0.03-0.03-0.03-0.04-0.03-0.04-0.03-0.02-0.02-0.13-0.13-0.03
R&D Expense -13.73M8.94M6.42M-6.49M6.27M6.56M-5.93M6.36M4.88M-4.96M5.24M4.27M-3.34M2.81M3.57M-3.39M2.93M2.81M-2.99M3.30M3.59M-4.18M3.87M3.74M-3.01M2.87M3.17M3.11M3.11M3.27M4.23M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.93M3.71M4.43M3.92M4.43M5.24M7.04M5.92M3.46M4.99M3.52M1.83M4.34M14.70M8.95M9.50M14.56M
Gross Profit -3.68M4.35M3.48M3.64M4.41M5.93M5.57M3.29M4.69M3.10M1.44M2.92M13.97M8.27M--
Operating Income -3.52M-9.85M-18.69M-25.00M-55.99M-50.68M-65.81M-58.97M-38.90M-41.80M-38.88M-26.45M-49.21M-22.52M-24.73M-21.48M-36.62M
Net Income -5.14M-11.18M-16.52M-21.43M-43.88M-36.41M-46.99M33.57M-19.98M-45.99M-11.71M-20.65M-43.02M-26.27M-21.49M-18.61M-63.53M
Diluted EPS ------0.55-0.590.34-0.17-----0.15-0.12-0.09-0.28
R&D Expense -3.18M8.19M13.70M18.12M26.61M37.53M42.60M36.11M24.02M20.95M17.95M12.32M33.91M13.99M15.71M12.47M17.73M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --53.27M45.83M29.75M57.73M74.90M94.66M142.57M173.24M101.66M125.48M107.95M174.54M123.66M101.02M113.22M112.58M
Total Equity -4.35M11.05M38.17M28.65M9.58M14.80M36.46M25.82M117.93M162.64M93.84M112.96M96.20M92.22M73.34M63.42M78.38M44.55M
Cash & Equivalents 12.28K12.19M33.32M22.21M4.35M5.50M29.49M42.23M22.09M36.84M23.59M9.50M32.59M55.74M11.36M35.44M45.79M40.79M
Total Liabilities -------18.21M12.06M8.98M9.41M14.23M12.82M83.65M51.73M39.00M36.21M69.24M
Current Liabilities --2.48M3.15M4.39M6.96M7.07M12.46M8.85M6.88M6.81M6.49M7.77M47.12M18.98M17.96M13.98M11.37M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.26M-7.73M-13.59M-19.68M-29.51M--44.54M-42.33M-30.52M-30.88M-31.95M-19.75M-23.56M1.06M-28.57M-23.09M-18.92M
Investing Cash Flow -46.23K3.20M-1.20M-104.69K-3.67M--7.44M-10.89M-10.22M11.82M16.96M13.04M9.74M-46.16M46.45M-2.31M-13.46M
Financing Cash Flow 16.48M25.77M3.86M1.91M34.26M-64.78M32.78M55.39M5.77M617.00K29.86M36.93M1.63M6.42M35.86M26.95M
Capital Expenditure -61.28K-220.77K-960.28K-400.81K-2.28M-483.00K-1.24M-2.25M-1.33M-556.00K-440.00K-64.00K-340.00K-413.00K-674.00K-565.00K-522.00K
Free Cash Flow -4.32M-7.95M-14.55M-20.08M-31.79M--45.78M-44.57M-31.84M-31.44M-32.39M-19.82M-23.90M646.00K-29.24M-23.66M-19.44M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -99.3%98.2%88.9%82.1%84.0%84.3%94.0%95.1%93.9%88.3%78.9%67.2%95.0%92.5%--
Operating Margin % -182.9%-265.7%-421.4%-638.5%-1,262.7%-966.5%-935.3%-995.6%-1,125.0%-837.9%-1,106.0%-1,448.4%-1,133.6%-153.2%-276.5%-226.1%-251.6%
Net Margin % -267.2%-301.6%-372.5%-547.2%-989.7%-694.4%-667.9%566.8%-577.7%-922.0%-333.1%-1,130.8%-991.0%-178.7%-240.2%-195.9%-436.5%
ROE % -46.6%-29.3%-57.7%-223.5%-296.5%-99.9%-182.0%28.5%-12.3%-49.0%-10.4%-21.5%-46.6%-35.8%-33.9%-23.7%-142.6%
ROCE % --19.4%-43.8%-98.6%-110.3%-74.7%-80.1%-44.1%-23.4%-44.1%-32.7%-26.4%-38.6%-21.5%-29.8%-21.6%-36.2%

Shareholding Pattern

Insiders
4.86%
Institutions
48.20%
Public Float
50.66%

Top Institutional Holders

#Holder% HeldSharesValue
1 Broadwood Capital, Inc. 19.60% 49.56M $51.05M
2 Blackrock Inc. 5.21% 13.19M $13.58M
3 Vanguard Capital Management LLC 3.58% 9.05M $9.33M
4 Defender Capital, LLC 2.61% 6.60M $6.80M
5 Geode Capital Management, LLC 2.10% 5.30M $5.46M
6 Raffles Associates Lp 2.06% 5.20M $5.35M
7 Fifth Third Bancorp 1.82% 4.60M $4.74M
8 Millennium Management Llc 1.19% 3.02M $3.11M
9 State Street Corporation 0.92% 2.31M $2.38M
10 Vanguard Fiduciary Trust Co 0.66% 1.67M $1.72M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LCTX

Google News ue, 08 Sep 2026

A cell-making system gets a U.S. patent expected to run through 2043 from Lineage Cell Therapeutics - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQQ3JzaXZDeHdEN2JvSUJuejJtVi1QdGJDU2lyUVJSWGZaV1RwSkM1OHFWTGhYZ0psLXk3R013YlJDQXlHcmdPY29SZ1EtLUxGaVNqR2lkVXJEWGFBVXVDMzVFX3FRZHB5czVxLWFJQTRWbUZSajRCal8tV1liakg3RHpxa0VsbUwxUkJYek…

Google News hu, 18 Jun 2026

Lineage Cell Therapeutics (LCTX) Stock Faces Mixed Analyst Target Changes After Fresh Coverage - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQenBlRTFvV09SeVdKUC1aWGtPUVhLckJKSUtUazd2X2NKb3o1blBqRzU0Rk56VTRmZmg1MzZQbDZOMi0zVVplSkxvYmxYSnBtbk9QQnJaRmNLbXYxaVhWYUxiMXUtRHo5QWtISUw2ZmR4VXZYMk1Dc05QdjBtNlJVa0pZZWgwcUZwbFBqaW…

Google News hu, 25 Jun 2026

LCTX Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBVdEVkczFtamI2OThuQmJQc1JuMmkwMTE1TU1lb0ZxNVBBVzVROTYwYTJmMjRnY2pINTcwZndSZWFBbEU4a0tXVXJramNhR3RvOUthQXROOWdNR1Vtamh2Vldsck5iZ3VIT0M0cGJnTVhHa1FWcWJr?oc=5" target="_blank">LCTX Fo…

Google News ue, 26 May 2026

LCTX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE43WEpVa0Z1Z21sSThyenRidWhkOU9JdXN4T29GdW9nWTlmWUEySFc0MmRwVkhUbUNvZGpWNHQ4cDcxTjJhZGc?oc=5" target="_blank">LCTX</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News hu, 04 Jun 2026

How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZTA0SlpmdDRHalpCcmlxemNxRldKc1NuOC1YaTJxWVNJdDU1RnhjaFY2aWQyaG9MbUZVMk5mS1RydHBYSGI0ZUF1d19scjVmN2hxYVdJa3V3M2p5MlRKbUZDUGE5Z25GQ0ZsQXRwSTZjVEdfVHRYUFROYk5TM0Nqb2VCRW9GMm1qWFRWN1…

Google News ue, 12 May 2026

Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment - ChartMill

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxNQkEzajZxLUVkbVFIQ2JlelNOczBqeVV5a2dpTmtSMVV5QjBzRXVneW9xb085S1VaTWk4RVJyVTNuYks2RmxQbEVoSTNCcW9KVEJPU0k1N0lXWm9BU1d6T1d6UDRwUzlIaE9Jd3BqdDlqcDU3alpnRFdQRE5CUE1mOWRqTDJTamtKNExrSD…

LCTX — Frequently Asked Questions

What is the current share price of Lineage Cell Therapeutics, Inc. (LCTX)?

As of 2026-09-19 21:16 PDT, Lineage Cell Therapeutics, Inc. (LCTX) trades at $1.09 on NYSE American. Its 52-week range is $1.02 to $1.96.

What is the market capitalisation of LCTX?

Lineage Cell Therapeutics, Inc. (LCTX) has a market capitalisation of $275.67M on NYSE American.

What is the P/E ratio of LCTX?

LCTX trades at a trailing price-to-earnings (P/E) ratio of -5.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.27.

What is the return on equity (ROE) of LCTX?

LCTX has a return on equity (ROE) of -60.06%. Its return on capital employed (ROCE) is -36.18%.

Is LCTX a good stock to buy?

This page provides a data-driven analysis of Lineage Cell Therapeutics, Inc. (LCTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space